Advertisement

Topics

Search Results for "Crizotinib Src Kinase"

03:24 EDT 19th October 2017 | BioPortfolio

Matching Channels

Polo like kinase Plk 1

Polo-like kinase (Plk) is an important cell cycle regulatory kinase that has been implicated in a multitude of cell cycle events. Plks form a family of four different proteins that regulates many as...

MAP kinase kinase MEK Inhibitors

The mitogen activated protein kinases (MAPKs) are conserved proteins that regulate cell growth, division and death.  The MAPK pathway has emerged as the crucial route between membrane-bound Ras...

Bcr Abl and Src Kinase Inhibitors

Chronic myeloid leukemia (CML) is characterized by the presence of the Philadelphia (Ph) chromosome, which results from a reciprocal translocation between the long arms of the chromosomes 9 and 22 t...

Checkpoint kinase 1 CHK 1

Progression through the cell cycle is monitored by surveillance mechanisms known as cell cycle checkpoints. Dysfunction in cell cycle checkpoints leads to genomic instability and contributes to tumo...

Kinases Raf Inhibitors

The Ras-Raf-MEK-ERK (ERK) pathway is a logical therapeutic target because it represents a common downstream pathway for several key growth factor tyrosine kinase receptors which are often mutated or...

Matching News

[Comment] Ascending role of next-generation ALK inhibitors

Anaplastic lymphoma kinase (ALK) gene rearrangements were first discovered in 5% of lung adenocarcinomas in 2007,1 and since then, these lung tumours have prompted a decade of breakneck development of...

Brigatinib Tablets (Alunbrig)

Brigatinib is indicated for the treatment of patients with anaplastic lymphoma kinase-positive metastatic non-small cell lung cancer who have progressed on or are intolerant to crizotinib.

Phase III study showed Roche’s Alecensa (alectinib) reduced the risk of disease progression or death by more than half versus crizotinib as first-line treatment in a specific type of lung cancer

Roche today announced that the phase III ALEX study showed Alecensa® (alectinib) significantly reduced the risk of disease worsening or death (progression-free survival, PFS) by more than half (53%) ...

Crizotinib Produced Robust Response in ALK-Positive Pediatric Lymphoma

Pediatric patients with ALK-positive anaplastic large cell lymphomas and inflammatory myofibroblastic tumors had strong responses to treatment with crizotinib.

[News] Alectinib surpasses crizotinib for untreated -positive NSCLC

Alectinib was more effective and less toxic than crizotinib in patients with treatment-naive non-small-cell lung cancer (NSCLC) harbouring rearranged ALK, according to results from the ALEX trial.

Phase III Study Showed Genentech’s Alecensa (Alectinib) Reduced the Risk of Disease Progression or Death by More Than Half Versus Crizotinib as First-Line Treatment in a Specific Type of Lung Cancer

Second positive Phase III head-to-head study to show Alecensa was superior to crizotinib in people with ALK-positive lung cancer Alecensa lowered the r...

ASCO 2017: Alectinib halts lung cancer growth more than a year longer than crizotinib

Findings from a phase III clinical trial point to a more effective initial treatment for patients with ALK-positive non-small cell lung cancer (NSCLC). Compared to the current standard of care crizot...

[Articles] Ceritinib versus chemotherapy in patients with -rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial

These findings show that patients derive significant clinical benefit from a more potent ALK inhibitor after failure of crizotinib, and establish ceritinib as a more efficacious treatment option compa...

Matching PubMed Articles

Successful oral desensitization with crizotinib after crizotinib-induced hepatitis in an anaplastic lymphoma kinase-rearranged non-small-cell lung cancer patient: A case report.

Crizotinib is one of the molecularly-targeted agents targeted against anaplastic lymphoma kinase (ALK)-rearranged non-small-cell lung cancer (NSCLC). Although its effects appear to be promising, crizo...

Alpha-tocopherol attenuates the anti-tumor activity of crizotinib against cells transformed by NPM-ALK.

Anaplastic large cell lymphomas (ALCL) are mainly characterized by harboring the fusion protein nucleophosmin-anaplastic lymphoma kinase (NPM-ALK). The ALK inhibitor, crizotinib specifically induced a...

Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.

The authors' previous study demonstrated that the B-cell chronic lymphocytic leukemia/lymphoma (Bcl-2)-like 11 (BCL2L11) (Bim) deletion polymorphism was associated with poor clinical response to epide...

Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.

Background Alectinib, a highly selective inhibitor of anaplastic lymphoma kinase (ALK), has shown systemic and central nervous system (CNS) efficacy in the treatment of ALK-positive non-small-cell lun...

Crizotinib, a MET inhibitor, prevents peritoneal dissemination in pancreatic cancer.

Peritoneal dissemination is a frequent occurrence in pancreatic cancer, which is associated with a poor prognosis. MET is associated with the progression of pancreatic cancer; therefore, we evaluated ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement